

# ForPatients

by Roche

Idiopathic Pulmonary Fibrosis (IPF)

## A Study to Evaluate Long Term Safety and Efficacy of Recombinant Human Pentraxin-2 (rhPTX-2; PRM-151) in Participants With Idiopathic Pulmonary Fibrosis

**Trial Status**  
Terminated

**Trial Runs In**  
28 Countries

**Trial Identifier**  
NCT04594707 2020-001429-30  
WA42294

---

The source of the below information is the publicly available website [ClinicalTrials.gov](https://clinicaltrials.gov). It has been summarised and edited into simpler language.

### *Trial Summary:*

This study will evaluate the long-term safety, efficacy and pharmacokinetics (PK) of recombinant human pentraxin-2 (rhPTX-2; PRM-151) zinpentraxin alfa, administered by intravenous (IV) infusion to participants with idiopathic pulmonary fibrosis (IPF).

**Hoffmann-La Roche**  
Sponsor

**Phase 3**  
Phase

---

**NCT04594707 2020-001429-30 WA42294**  
Trial Identifiers

---

### *Eligibility Criteria:*

**Gender**  
All

**Age**  
All

**Healthy Volunteers**  
No

---